Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

April 2019

Specialty Pharmacy Program Updates


Harvard Pilgrim’s Specialty Pharmacy Program has added the following medications:

Name & Indication

Coverage

Available From

Xospata (gilteritinib) Treatment of adults who have relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation as detected by an FDA-approved test

Pharmacy

Limited Distribution Drug: Onco 360

Daurismo (glasdegib) Used in combination with low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia.

Pharmacy

CVS Specialty Non-Mandatory

Vitrakvi (larotrectinib) Used in the treatment of certain adult and pediatric patients with solid tumors.

Pharmacy

Limited Distribution Drug: CVS Specialty

Lorbrena (lorlatinib) Used to treat certain patients with non-small cell lung cancer.

Pharmacy

CVS Specialty Non-Mandatory

Talzenna (talazoparib) Used to treat adults with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.

Pharmacy

CVS Specialty Non-Mandatory

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Improved Functionality, New Design for HPHConnect Referrals

Submitting Claims for Fidelity, Sedgwick, and Nielsen Members

Shared Decision-Making Tools for Members and Providers

CLINICIAN CORNER

NICU Program with ProgenyHealth Begins June 1

Emergency Department Overuse

Advance Care Planning Coverage (99497 & 99498)

Complex Case Management Services

Disease Management Programs Reinforce Physician Treatment Plans

Prior Authorization Required for Ilumya

Prior Authorization for Cutaquig and Libtayo

Prior Authorization Required for Onpattro

Alcohol and Drug Use Disorder: Treatment and Helpful Resources

Pharmacy and Therapeutics Committee Meeting Update

Specialty Pharmacy Program Updates

OFFICE ASSISTANT

Correct Use of Modifiers 58, 78, and 79

PUBLICATION INFORMATION

Robert Farias,
Senior Vice President, Corporate Network Strategy

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator